Novartis AG (NVS)

86.88
0.35 0.40
NYSE : Health Technology
Prev Close 87.23
Open 86.54
Day Low/High 86.36 / 86.92
52 Wk Low/High 74.97 / 96.31
Volume 995.88K
Avg Volume 1.89M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 220.45B
EPS 5.50
P/E Ratio 16.21
Div & Yield 1.84 (2.12%)

Initiating a Pharmaceutical Name and a Small Retail Trim

We are bringing Novartis out of the bullpen and into the portfolio.

Stocks to Watch on Volatility

A menu of stocks and associated price levels where we think a bit of nibbling and small buying is worth doing.

INVESTOR ALERT: Law Offices Of Howard G. Smith Continues Its Investigation On Behalf Of Novartis AG Investors (NVS)

INVESTOR ALERT: Law Offices Of Howard G. Smith Continues Its Investigation On Behalf Of Novartis AG Investors (NVS)

Law Offices of Howard G. Smith continues its investigation on behalf of Novartis AG ("Novartis" or the "Company") (NYSE: NVS) investors concerning the Company and its officers' possible violations of federal securities laws.

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Novartis AG And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Novartis AG And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG ("Novartis" or "the Company") (NYSE: NVS) for violations of §§10(b) and 20(a) of the Securities Exchange...

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Novartis AG - NVS

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Novartis AG - NVS

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business...

Amgen Declines Following Mizuho Downgrade to Neutral

Amgen Declines Following Mizuho Downgrade to Neutral

Amgen's rating is lowered at Mizuho but its price target gets raised to $212.

Charts of Alcon Look Good

Charts of Alcon Look Good

Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.

Boom or Bust?: Cramer's 'Mad Money' Recap (Thursday 8/15/19)

Boom or Bust?: Cramer's 'Mad Money' Recap (Thursday 8/15/19)

It's not really a boom or a bust, says Jim Cramer. The truth is we're muddling along. But it's hard to outrun the bond bears.

It's Tough to Weed Through the Data on Tilray

It's Tough to Weed Through the Data on Tilray

The largest impediment to success for firms like TLRY -- which is expected to report a 27 cent loss per share Tuesday night -- remains federal legalization of marijuana across the U.S.

Tilray Stock Gains Ahead of Highly Anticipated Earnings Release

Tilray Stock Gains Ahead of Highly Anticipated Earnings Release

Tilray will look to sustain a sanguine sentiment on cannabis stocks on Tuesday.

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.

Amgen Climbs After Winning Patent Case on Enbrel

Amgen Climbs After Winning Patent Case on Enbrel

Amgen's patents for Enbrel likely to be protected until 2029.

Novartis (NVS) Alert: Johnson Fistel Launches Investigation Into Novartis AG; Investors Encouraged To Contact Firm

Novartis (NVS) Alert: Johnson Fistel Launches Investigation Into Novartis AG; Investors Encouraged To Contact Firm

SAN DIEGO, Aug. 7, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Novartis AG ("Novartis") (NYSE: NVS) for violations of federal securities laws.

Bullpen Update

These companies already posted strong earnings this season and are not economically sensitive.

FDA Says Some Data From Novartis Gene Therapy Manipulated

FDA Says Some Data From Novartis Gene Therapy Manipulated

The FDA says some data from the testing of Novartis's gene-therapy product Zolgensma was manipulated, but the drug should stay on the market.

Dow Finished Up 300 Points, Rebound From Worst Day of the Year

Dow Finished Up 300 Points, Rebound From Worst Day of the Year

The Dow ends up over 300 points on Tuesday, bouncing back one day after its worst session of the year so far.

Should You Go for the 'Easy Money' in Novartis?

Should You Go for the 'Easy Money' in Novartis?

NVS been in an uptrend the past twelve months.

Go for the Easy Money: Cramer's 'Mad Money' Recap (Thursday 7/18/19)

Go for the Easy Money: Cramer's 'Mad Money' Recap (Thursday 7/18/19)

Jim Cramer says Netflix just went from being an easy-money stock to a hard-money stock. Investors need to know the difference.

Jim Cramer: Looking for Netflix Action? Don't Be a Hero

Jim Cramer: Looking for Netflix Action? Don't Be a Hero

Stranger things have happened, but with NFLX's subscriber miss, the stock just became hard money, joining the likes of Johnson & Johnson and CSX Corp.

Novartis Up on Financial Results and Potential Resolution of Kickback Case

Novartis Up on Financial Results and Potential Resolution of Kickback Case

Swiss drug company sees stock rise following latest earnings report.

What Is a Target-Date Fund? Definition and Example

What Is a Target-Date Fund? Definition and Example

Looking for a new retirement option? Target-date funds might be the right fit for you.

Mylan Falls on Report That EpiPen Shortage Is Hurting Patients and Pharmacists

Mylan Falls on Report That EpiPen Shortage Is Hurting Patients and Pharmacists

Novartis said earlier this week it would make a generic EpiPen to fill the void of Mylan's shortage.

Biogen Drops After Piper Jaffray Downgrade, Price Target Cut

Biogen Drops After Piper Jaffray Downgrade, Price Target Cut

The firm now has a neutral rating on Biogen based on data from a new neurologist survey.

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

Long-term Survival Benefit Shown For Metastatic Melanoma Patients Treated With Novartis Tafinlar® Mekinist®

Long-term Survival Benefit Shown For Metastatic Melanoma Patients Treated With Novartis Tafinlar® Mekinist®

- Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine

Novartis Shows Growing Strength In Lung Cancer Innovation With New Capmatinib Investigational Data And Novel Canakinumab Clinical Trials

Novartis Shows Growing Strength In Lung Cancer Innovation With New Capmatinib Investigational Data And Novel Canakinumab Clinical Trials

- Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon-14 skipping mutation

AveXis Receives FDA Approval For Zolgensma®, The First And Only Gene Therapy For Pediatric Patients With Spinal Muscular Atrophy (SMA)

AveXis Receives FDA Approval For Zolgensma®, The First And Only Gene Therapy For Pediatric Patients With Spinal Muscular Atrophy (SMA)

- SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1,2]

Stocks We Are Looking at During Thursday's Early Declines

Our preference is to make smaller, incremental buys as the market comes in.

Jim Cramer: Trump Cares More About Beating the Chinese Than Earnings Reports

Jim Cramer: Trump Cares More About Beating the Chinese Than Earnings Reports

Jim Cramer weighs in on why President Trump cares more about 'beating the Chinese' than the earnings reports that we receive from companies.

Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point

Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point

Let's review the charts and indicators this morning.

TheStreet Quant Rating: A- (Buy)